en · de · es · fr · pt
semax-notes.peptides6823.com › Info › Semax Peptide Background And Identity — Field Notes

Semax Peptide Background And Identity — Field Notes

By Editorial Desk · published 2025-10-13 · last reviewed 2025-11-29 · Info

heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-11-29. Numbers and descriptions here follow the published literature rather than marketing material.

Semax Peptide Background and Identity

Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.

Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.

Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.

Semax Background and Chemistry

The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.

Semax at a glance

PropertyValueNotes
Chemical classSynthetic heptapeptide (ACTH fragment analog)Not a steroid; does not belong to the melanocortin agonist drugs by marketing category
Molecular formulaC37H51N9O10S (commonly cited)Reported values vary slightly with salt and counter-ion content
AppearanceWhite to off-white lyophilized powderA single batch may appear as a loose cake or fluffy solid
SolubilityFreely soluble in water and aqueous bufferStock solutions are usually prepared in sterile water or saline
Typical storage−20 °C or below, desiccated and protected from lightSeal opened vials promptly to limit moisture uptake

Semax 的分子背景与结构

该化合物于二十世纪八十年代在俄罗斯被开发,相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性,而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示,这一方向促成了多个相关短肽的合成与筛选,而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。

研究兴趣主要集中在神经营养因子相关的路径上,包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升,但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验,人体对照研究数量有限。因此,该化合物的作用机制在文献中属于活跃讨论,而非已经确立的定论。

Related pages on this site

Background and Development History

Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.

The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.

Semax Peptide Structure and Origin

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.

The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.

Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.

Background and Development

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Notes from published material

This version of the song, which features Maynard James Keenan (from Tool and A Perfect Circle) and guitarist John Frusciante (of the Red Hot Chili Peppers), was praised by Aicher as "Dark, brooding, sad, and twitchy".

=== Discontinuation === The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse. Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite. Other symptoms may include restlessness, increased sweating, and trouble sleeping. Less commonly there may be a feeling of the world spinning, numbness, or muscle pains. Symptoms generally resolve after a short period of time. There is tentative evidence that discontinuation of antipsychotics can result in psychosis. It may also result in reoccurrence of the condition that is being treated. Rarely tardive dyskinesia can occur when the medication is stopped.

To ensure highly anisotropic, yet predictable solidification behavior within the SSZ, dynamic freezing patterns are preferred. Using dynamic freezing, the velocity of the solidification front, and, therefore, the ice crystal size, can be controlled with a changing temperature gradient. The increasing thermal gradient counters the effect of the growing thermal buffer imposed by the growing ice front. It has been shown that a linearly decreasing temperature on one side of a freeze-cast will result in near-constant solidification velocity, yielding ice crystals with an almost constant thickness along the SSZ of an entire sample. However, as pointed out by Waschkies et al. even with constant solidification velocity, the thickness of the ice crystals does increase slightly over the course of freezing. In contrast to that, Flauder et al. demonstrated that an exponential change of the temperature at the cooling plate leads to a constant ice crystal thickness within the complete SSZ, which was attributed to a measurably constant ice-front velocity in a distinct study. This approach enables a prediction of the ice-front velocity from the thermal parameters of the suspension. Consequently, if the exact relationship between the pore diameter and ice-front velocity is known, an exact control over the pore diameter can be achieved.

=== Fermentation === The company Evolva has developed a genetically modified yeast which can produce vanillin. Because the microbe is a processing aid, the resulting vanillin would not fall under U.S. GMO labeling requirements, and because the production is nonpetrochemical, food using the ingredient can be said to contain no artificial ingredients. The biosynthetic process starts with glucose, or any sugar that can be converted into erythrose 4-phosphate (which leads to 3-dehydroshikimic acid). The end product is 98% pure and is also considered natural in the EU. Using ferulic acid (a chemical found in rice) as an input and a specific non GMO species of Amycolatopsis bacteria, vanillin can be produced. Many other bacteria, either GMO or non-GMO, can be used for the same purpose. However, because vanillin inhibits the growth of free-floating bacteria, yields have been low. This can be overcome through the formation of biofilms, which has been done with the non-GMO B. subtilis strain CCTCC M2011162. However, using ferulic acid as the starting material does not qualify for "natural ingredient" in the EU. Biotransformation of eugenol (from cloves) into vanillin by non-GMO microorganisms has also been reported. The same has been reported for guaiacol and guaicyl lignin (from conifers). These starting materials do not qualify for "natural ingredient" in the EU.

In addition to its role as a natural hormone, estradiol is used as a medication, for instance in menopausal hormone therapy, and feminizing hormone therapy for transgender women and some genderqueer individuals; for information on estradiol as a medication, see the estradiol (medication) article.

Sources: en.wikipedia.org

Further detail

== External links == The MEROPS online database for peptidases and their inhibitors: S01.001 Archived 2019-09-15 at the Wayback Machine Chymotrypsin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)

==== Sub-Divisions ==== Each Sub-Division is headed by one Police officer of the rank Deputy Superintendent of Police (members of West Bengal Police Service, a directly recruited officer or one promoted from the ranks) or an Assistant Superintendent of Police (members of Indian Police Service). In West Bengal, the officer who heads a Sub-Division is known as SDPO i.e. Sub Divisional Police Officer.

The Mediterranean coast was well known to the Carthaginians. Their close relations with Phoenician-Punic settlements and shared cultural ties likely gave them considerable political and economic influence there from the 6th or 5th century BC, alongside the establishment of unequal treaties with Iberian city-states. After Carthage's defeat by Rome in the First Punic War, it sought new western territories, culminating in the Barcid conquest of the Iberian Peninsula in 237 BC. The Romans invaded the Iberian Peninsula in 218 BC and expelled the Carthaginians after the Battle of Ilipa in 206 BC. Within 200 years, mainland Portugal had been annexed by the Romans despite resistance from local tribes such as the Lusitanians under the leadership of Viriathus and other leaders. In 409, with the decline of the Western Roman Empire, the Iberian Peninsula was invaded by Germanic tribes. Western Iberia was integrated into the Suebian Kingdom, with its capital in or near Braga. The Visigoths defeated the Suebi in 585 and ruled the peninsula until the early 8th century. In 711, the Iberian Peninsula was invaded from the south by the Umayyad Caliphate, which expanded rapidly. By 716, present-day mainland Portugal was part of the Muslim Iberian territories known as al-Andalus.

The seeds contain saponins but no calcium oxalate raphide crystals, chelidonic acid (unlike Asparagales) or cysteine derived sulphur compounds (allyl sulphides), another distinguishing feature from the characteristic alliaceous odour of the Allioideae. Fritillaria in particular contains steroidal alkaloids of the cevanine and solanum type. Solanidine and solanthrene alkaloids have been isolated from some Fritillaria species. Tulipa contains tulipanin, an anthocyanin.

Sources: en.wikipedia.org

Frequently asked questions

What is Semax made of?

It is a short synthetic peptide built from seven amino acids: methionine, glutamic acid, histidine, phenylalanine and three prolines. The sequence derives from the 4-10 fragment of adrenocorticotropic hormone with an added proline-glycine-proline tail. No plant or animal extract is involved; the material is produced by solid-phase peptide synthesis.

Where did Semax originate?

It was developed in the Soviet Union during the early 1980s by groups at the Institute of Molecular Genetics in Moscow. Russian approval for intranasal use followed, and it has been marketed there since. Western laboratories encountered it mainly through translated literature and, later, through online research-chemical trade.

Is Semax a licensed medicine?

It holds a Russian registration as a prescription nasal product but has no approval from the European Medicines Agency or the United States Food and Drug Administration. Buyers outside Russia usually receive material sold strictly for laboratory research. That distinction matters because research-grade and pharmaceutical-grade products carry different documentation and testing expectations.

Is semax an approved medicine?

It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.

Network